Comparative evaluation and preference of MixPro® versus Mix2Vial® reconstitution devices among people with haemophilia and caregivers

Jon Ulrich Hansen; Cléa Percier; Henrik Damgaard-Rasmussen; Katherine Palmer

doi:10.2478/jhp-2022-0012

Abstract

Abstract Introduction

People with haemophilia (PwH) require frequent infusions with plasma-derived or recombinant coagulation factors to help prevent and treat acute bleeding episodes. This ‘replacement therapy’ can be administered at home by PwH or their caregivers using a drug reconstitution device. MixPro^® and Mix2Vial^® are two such devices.

Aims/Objectives

To compare the experiences and evaluate the preferences of PwH and caregivers using two reconstitution devices: MixPro^® and Mix2Vial^®.

Methods

Qualitative interviews were conducted between the 22 June and 4 August 2021 with male PwH or caregivers of PwH. Participants were asked questions about the reconstitution devices they have used in general, followed by questions relating specifically to the MixPro^® or Mix2Vial^® devices. Demonstration devices were provided to all participants during the interview.

Results

In total, 105 participants (71 PwH and 34 caregivers) were interviewed in the USA, Italy, UK, and Japan. PwH had a mean age of 29 years (3–69 years). Overall, participants reported the number of parts, speed of reconstitution, and ease of use to be the largest unmet needs with reconstitution devices. Regarding the device features, low contamination risk was ranked as most important (importance score: 15.1) for all countries except Italy, where portability of the device was most important (11.7 for portability vs. 10.6 for low contamination risk). When MixPro^® and Mix2Vial^® features were independently evaluated, MixPro^® outperformed Mix2Vial^® across 17 of the 18 features; both devices were rated equally for low contamination risk. When asked which device performed best on each feature, MixPro^® was chosen by the majority of participants (74%). MixPro^® was associated with words such as quick (54%), user-friendly (47%), and easy (46%), while Mix2Vial^® was associated with the words easy (33%), safe (32%), and awkward (30%). Participants felt MixPro^® would make a positive difference to their lives citing reasons such as saving time, ease of portability, and general confidence in using the system. Relatively few participants thought Mix2Vial^® would make a positive difference to their lives, with some noting it was not much different than the previous generation of devices.

Conclusion

In this study, MixPro^® was preferred over Mix2Vial^® as a reconstitution device for PwH and caregivers of PwH.

Article

View Full Article

References

1. Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D. Establishing the prevalence and prevalence at birth of hemophilia in males. Ann Intern Med 2019; 171(8): 540–6. doi: https://doi.org/10.7326/m19-1208%m31499529.
2. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(S6): 1–158. doi: https://doi.org/10.1111/hae.14046.
3. Munn J, Khair K, Scott A, et al. Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro^®). J Haem Pract 2016; 3(1): 33–8. doi: https://doi.org/10.17225/jhp00073
4. Poonnoose P, Carneiro JDA, Cruickshank AL, et al. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the MUSFIH study. Haemophilia 2017; 23(4): doi: 538–46. https://doi.org/10.1111/hae.13242.
5. van den Berg HM. From treatment to prevention of bleeds: what more evidence do we need? Haemophilia 2017; 23(4): 494–6. doi: https://doi.org/10.1111/hae.13256.
6. Centers for Disease Control and Prevention. Community Counts Registry Report – Males with Hemophilia 2014–2017. 16. Treatment / Treatment Regimen and Hemophilia Severity; 2020. Available from: https://www.cdc.gov/ncbddd/hemophilia/communitycounts/registry-report-males/treatment.html (accessed 28 July 2022).
7. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10(2): 165–8. doi: https://doi.org/10.2450/2012.0147-11.
8. Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49–56. doi: https://doi.org/10.2147/jbm.S43734.
9. Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8(4): 292–6. doi: https://doi.org/10.2450/2010.0067-10.
10. Mannucci PM. Hemophilia and related bleeding disorders: a story of dismay and success. Hematology Am Soc Hematol Educ Program 2002; 1–9. doi: https://doi.org/10.1182/asheducation-2002.1.1.
11. United States Government. Federal Register. Determination of regulatory review period for purposes of patent extension: antihemophilic factor concentrate (recombinant). Washington DC, USA; 1993.
12. Pfizer; Wyeth Pharmaceuticals LLC. BeneFIX^®: Highlights of prescribing information. Revised 4/2021. Available from: https://www.fda.gov/media/73556/download (accessed 28 July 2022).
13. Musso R, Santoro R, Coppola A, et al. Patient preference for needleless factor VIII reconstitution device: the Italian experience. Int J Gen Med 2010; 3: 203–8. doi: https://doi.org/10.2147/ijgm.s12096.
14. Cimino E, Linari S, Malerba M, et al. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713–20. doi: https://doi.org/10.2147/PPA.S64709.
15. Ingle RG, Fang W-J. Prefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system. Int J Pharm 2021; 597: 120314. doi: https://doi.org/10.1016/j.ijpharm.2021.120314.
16. Pollard D, Khair K, Percier C, Wong Y, Shoemark R. Evaluation of a pre-filled diluent syringe (MixPro) among patient/carer users and nurses. J Haem Pract 2018; 5(1): 12–23. doi: https://doi.org/10.17225/jhp00106.
17. Novo Nordisk. NovoSeven RT coagulation factor VIIa (recombinant). 2019. Available from: https://www.novosevenrtpro.com/resources/patient-support/patient-education/mixpro-brochure.html (accessed 28 July 2022).
18. West Pharmaceutical Services. Mix2Vial. 2017. Available from: https://www.westpharma.com/-/media/WestPharma/Files/Products/Mix2Vial-Information-Sheet.pdf (accessed 28 July 2022).
19. Octapharma USA Inc. WILATE: Highlights of prescribing information. Revised September 2019. Available from https://www.fda.gov/media/77812/download (accessed 28 July 2022).
20. Grifols Biologicals LLC. Alphanate: Highlights of prescribing information. Revised 06/2018. Available from: https://www.grifols.com/documents/260038/65508/ft-alphanate-us-en/a9f2f9c9-05eb-4fac-a7d3-5f091c198cff (accessed 28 July 2022).
21. Grifols Biologicals LLC. Coagulation factor IX (human); AlphaNine^® SD. Revised July 2013. Available from: https://www.grifols.com/documents/260038/89417/ft_alphanine_malasia_EN/a1bc830a-346a-474f-8bcc-4faca132c559 (accessed 29 July 2022).
22. CSL Behring. Idelvion: Summary of product characteristics. 2016; last updated 15/12/2021. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 28 July 2022).
23. CSL Behring. Hexilate: Highlights of prescribing information. Revised 5/2016. Available from: https://labeling.cslbehring.com/PI/US/HelixateFS/EN/HelixateFS-Prescribing-Information.pdf (accessed 28 July 2022).
24. Novo Nordisk. Novoeight: antihemophilic factor (recombinant): Highlights of prescribing information. 07/2020. Available from: https://www.novo-pi.com/novoeight.pdf (accessed 28 July 2022).
25. Novo Nordisk. Refixia: Summary of product characteristics. 2017; last updated 07/03/2022. Available from: https://www.ema.europa.eu/en/documents/product-information/refixiaepar-product-information_en.pdf (accessed 28 July 2022).
26. Genentech, Inc. HEMLIBRA^® (emicizumab): Highlights of prescribing information. Revised: 11/2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed 28 July 2022).
27. Bradley-Terry model. Encyclopedia of Mathematics. Revision 24 March 2012. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=22181 (accessed 28 July 2022).
28. Bradley-Terry model. Encyclopedia of Mathematics. Revision 30 May 2020. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=46143 (accessed 28 July 2022).
29. Novo Nordisk. Rebinyn: Highlights of prescribing information. Revised 06/2017. Available from: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---REBINYN.pdf (accessed 28 July 2022).

Comparative evaluation and preference of MixPro® versus Mix2Vial® reconstitution devices among people with haemophilia and caregivers

Abstract

Article

References

PDF Download

Authors

Jon Ulrich Hansen

Cléa Percier

Henrik Damgaard-Rasmussen

Katherine Palmer